Xeris Biopharma Holdings, Inc. (XERS) Financials
XERS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 340.8 million | 347.6 million |
2023-09-30 | 327.8 million | 323.9 million |
2023-06-30 | 328.8 million | 315.1 million |
2023-03-31 | 321.4 million | 291.3 million |
XERS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 6.2 million | 2.8 million |
2023-09-30 | -15.0 million | 2.5 million |
2023-06-30 | -15.3 million | 2.9 million |
2023-03-31 | -26.4 million | 2.6 million |
XERS Net Income
No data available :(
XERS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 72.5 million | - | 38.3 million |
2023-09-30 | 66.0 million | - | 37.5 million |
2023-06-30 | 80.7 million | - | 36.8 million |
2023-03-31 | 95.1 million | - | 10.8 million |
XERS Shares Outstanding
XERS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 132000 | 6.4 million | 37.6 million | - |
2023-09-30 | 345000 | 5.0 million | 37.3 million | - |
2023-06-30 | 1.5 million | 6.1 million | 37.6 million | - |
2023-03-31 | 238000 | 4.8 million | 33.6 million | - |
XERS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 44.4 million | 10.3 million |
2023-09-30 | 48.3 million | 8.2 million |
2023-06-30 | 38.0 million | 7.6 million |
2023-03-31 | 33.2 million | 5.3 million |
XERS
Price: $1.89
52 week price:
Earnings Per Share: -0.45 USD
P/E Ratio: -6.24
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 485000
Market Capitalization: 266.2 million